Advocating for the Rare Disease Community

11.07.13 | By

Have you heard of  Batten disease? Or  of Pompe disease? Niemann-Pick Disease? These are just a few of the 7,000 rare diseases that over 30 million Americans live with every day. Another rare disease that you may not be familiar with is Mitochondrial disease. Unfortunately, Art Estopian is too familiar with the disease. Art’s son, Arturo was diagnosed with thymidine kinase 2, mitochondrial disease, an inherited condition that causes progressive muscle weakness.

Sharing Takeaways from Alzheimer's Thought Leaders

11.05.13 | By

Today, Alzheimer’s affects more than five million people in America. According to the Alzheimer’s Association, that number will triple in the next 40 years, and by 2050, caring for patients with Alzheimer’s and other forms of dementia is expected to cost the United States more than $1 trillion annually. Given the tremendous looming human and financial costs, more and more attention and resources are being devoted to finding new ways to treat those with Alzheimer’s disease and, ultimately, find a cure.

Expanding Knowledge to Enhance Patient Wellness

11.02.13 | By

The old adage that 'you learn something new every day' doesn’t apply to the biopharmaceutical industry; for those researching and developing new medicine, it would be more accurate to say you learn something new every few minutes. Our member companies continue to push the limits of research, and that process keeps our work consistently exciting.
 

Developing Cures for Cancer

10.29.13 | By

A survey commissioned earlier this year by PhRMA shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities.

Conversations

Are we doing enough to ensure the security of our nation’s pharmaceutical supply chain?

Contributors Respond

The Fight Against Cancer

10.22.13 | By

According to the American Cancer Society, nearly one of every two people will develop a cancer at some point in their life.

Greater collaboration is key to improving patient outcomes

10.21.13 | By

More than 30 million Americans suffer from rare diseases – conditions that are classified as such because they affect fewer than 200,000 people in the United States. Fortunately, there are more than 450 new medications in the pipeline to treat these conditions, and one-third of all new drug approvals over the last five years have been for medicines specific to rare diseases.

Conversations Contributors - Peter L. Saltonstall

Peter is NORD’s President and Chief Executive Officer. He has over 30 years of healthcare experience in both for-profit and not-for-profit environments, as well as extensive federal and commercial market knowledge. Peter has held senior positions within a number of major academic medical centers and organizations, including Harvard's Brigham and Women's Hospital, Tufts-New England Medical Center and St. Elizabeth's Medical Center of Boston.

Connecting Patients, Families, and Advocates

10.11.13 | By

Every day, our industry strives to connect patients, families and advocates from across the globe who share our common goals of preventing diseases, improving health and saving lives. Those strong voices of innovators and stakeholders working tirelessly to address pressing medical challenges, and many medical breakthroughs wouldn’t be possible today or in the future without them.

Conversations Contributors - Beth McGinn

Beth McGinn is a political communications veteran of Capitol Hill and several congressional campaigns. She currently handles all media relations activities for the American Road & Transportation Builders Association.

Before coming to ARTBA, McGinn served as communications director for the House Judiciary Committee and spent several years as spokesperson for the Chairman Lamar Smith (R-Texas).  

Pages

Subscribe to RSS - conversations